Copeland T P, Creasman J M, Seidenwurm D J, Franc B L
Radiology and Biomedical Imaging and.
Clinical and Translational Science Institute, University of California-San Francisco, San Francisco, CA, U.S.A.
Curr Oncol. 2017 Apr;24(2):e99-e105. doi: 10.3747/co.24.3216. Epub 2017 Apr 27.
In the present study, we retrospectively evaluated the use of tomographic imaging in adult cancer patients to clarify how recent growth plateaus in the use of tomographic imaging in the United States might have affected oncologic imaging during the same period.
At a U.S. academic cancer centre, 12,059 patients with dates of death from January 2000 through December 2014 were identified. Imaging was restricted to brain and body computed tomography (ct), brain and body magnetic resonance (mr), and body positron-emission tomography (pet) with and without superimposed ct. Trends during the staging (1 year after diagnosis), monitoring (18-6 months before death), and end-of-life (final 6 months before death) phases were analyzed.
Comparing the 2005-2009 with the 2010-2014 period, mean intensity of pet imaging increased 21% during staging ( = 0.0000) and 27% during end of life ( = 0.0019). In the monitoring phase, mean intensity for ct brain, ct body, and mr body imaging decreased by 26% ( = 0.0133), 11% ( = 0.0118), and 26% ( = 0.0008), respectively. Aggregate mean intensity of imaging increased in the 13%-27% range every 3 months from 18 months before death to death, reaching 1.43 images in the final 3 months of life. Patients diagnosed in the final 18 months of life had an average of 1 additional image during both the 3 months after diagnosis ( = 0.0000) and the final 3 months before death ( = 0.0000).
Imaging increased as temporal proximity to death decreased, and patients diagnosed near death received more staging imaging, suggesting that imaging guidelines should consider imaging intensity within the context of treatment phase. Despite the development, by multiple organizations, of appropriateness criteria to reduce imaging utilization, aggregate per-patient imaging showed insignificant changes. Simultaneous fluctuations in the intensity of imaging by modality suggest recent changes in the modalities preferred by providers.
在本研究中,我们回顾性评估了断层成像在成年癌症患者中的应用情况,以阐明美国断层成像使用量近期的增长平稳期可能如何影响了同期的肿瘤成像。
在美国一家学术癌症中心,确定了12059例在2000年1月至2014年12月期间有死亡日期的患者。成像检查仅限于脑部和身体计算机断层扫描(CT)、脑部和身体磁共振成像(MR)以及有或无叠加CT的身体正电子发射断层扫描(PET)。分析了分期(诊断后1年)、监测(死亡前18 - 6个月)和临终(死亡前最后6个月)阶段的趋势。
将2005 - 2009年与2010 - 2014年期间进行比较,PET成像的平均强度在分期时增加了21%(P = 0.0000),在临终时增加了27%(P = 0.0019)。在监测阶段,脑部CT、身体CT和身体MR成像的平均强度分别下降了26%(P = 0.0133)、11%(P = 0.0118)和26%(P = 0.0008)。从死亡前18个月到死亡,成像的总体平均强度每3个月在13% - 27%的范围内增加,在生命的最后3个月达到1.43次成像。在生命最后18个月内确诊的患者在诊断后3个月(P = 0.0000)和死亡前最后3个月(P = 0.0000)平均多接受1次成像。
随着与死亡时间接近程度的降低,成像检查增加,且临近死亡时确诊的患者接受了更多的分期成像检查,这表明成像指南应在治疗阶段的背景下考虑成像强度。尽管多个组织制定了降低成像检查利用率的适宜性标准,但每位患者的总体成像检查显示变化不显著。不同成像方式强度的同时波动表明提供者近期对成像方式的偏好发生了变化。